The pharmacological inhibitors of poly (ADP-ribose) polymerase (PARP) family of proteins
have shown promising results in preclinical studies and clinical trials as a monotherapy or in …

The ubiquitin-proteasome axis has been extensively explored at a system-wide level, but the
impact of deubiquitinating enzymes (DUBs) on the ubiquitinome remains largely unknown …

The response to DNA double-strand breaks (DSBs) requires alterations in chromatin
structure to promote the assembly of repair complexes on broken chromosomes. Non …

Although protein ADP-ribosylation is involved in diverse biological processes, it has
remained a challenge to identify ADP-ribose acceptor sites. Here, we present an …

Among the earliest responses of mammalian cells to DNA damage is catalytic activation of a
nuclear enzyme poly (ADP-ribose) polymerase-1 (PARP-1). Activated PARP-1 forms the …

The autosomal recessive immunodeficiency, centromeric instability, and facial anomalies
(ICF) syndrome is a genetically heterogeneous disorder. Despite the identification of the …

Cells employ global genome nucleotide excision repair (GGR) to eliminate a broad
spectrum of DNA lesions, including those induced by UV light. The lesion-recognition factor …

Poly (ADP-ribosyl) ation is an essential post-translational modification with the biopolymer
poly (ADP-ribose)(PAR). The reaction is catalyzed by poly (ADP-ribose) polymerases …

Background Combining photon or proton radiotherapy with targeted therapy shows promise
for head and neck cancer (HNSCC). The poly (adenosine diphosphate [ADP]‐ribose) …

PARP inhibitors (PARPi), such as Olaparib, have shown promising results in high-grade
serous (HGS) epithelial ovarian cancer (EOC) treatment. PARPi sensitivity has been mainly …